These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 24306423)

  • 1. Antiangiogenic and antitumoral effects mediated by a vascular endothelial growth factor receptor 1 (VEGFR-1)-targeted DNAzyme.
    Shen L; Zhou Q; Wang Y; Liao W; Chen Y; Xu Z; Yang L; Sun LQ
    Mol Med; 2013 Nov; 19(1):377-86. PubMed ID: 24306423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arg-Leu-Tyr-Glu tetrapeptide inhibits tumor progression by suppressing angiogenesis and vascular permeability via VEGF receptor-2 antagonism.
    Baek YY; Lee DK; Kim J; Kim JH; Park W; Kim T; Han S; Jeoung D; You JC; Lee H; Won MH; Ha KS; Kwon YG; Kim YM
    Oncotarget; 2017 Feb; 8(7):11763-11777. PubMed ID: 28052029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of deoxyribozymes targeting c-Jun on solid tumor growth and angiogenesis in rodents.
    Zhang G; Dass CR; Sumithran E; Di Girolamo N; Sun LQ; Khachigian LM
    J Natl Cancer Inst; 2004 May; 96(9):683-96. PubMed ID: 15126605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EBV-LMP1 targeted DNAzyme enhances radiosensitivity by inhibiting tumor angiogenesis via the JNKs/HIF-1 pathway in nasopharyngeal carcinoma.
    Yang L; Liu L; Xu Z; Liao W; Feng D; Dong X; Xu S; Xiao L; Lu J; Luo X; Tang M; Bode AM; Dong Z; Sun L; Cao Y
    Oncotarget; 2015 Mar; 6(8):5804-17. PubMed ID: 25714020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of a novel anti-vascular endothelial growth factor receptor-1 monoclonal antibody that does not interfere with ligand binding.
    Graziani G; Ruffini F; Tentori L; Scimeca M; Dorio AS; Atzori MG; Failla CM; Morea V; Bonanno E; D'Atri S; Lacal PM
    Oncotarget; 2016 Nov; 7(45):72868-72885. PubMed ID: 27655684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties.
    Nakamura K; Taguchi E; Miura T; Yamamoto A; Takahashi K; Bichat F; Guilbaud N; Hasegawa K; Kubo K; Fujiwara Y; Suzuki R; Kubo K; Shibuya M; Isae T
    Cancer Res; 2006 Sep; 66(18):9134-42. PubMed ID: 16982756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VEGFR-1 targeted DNAzyme via transcatheter arterial delivery influences tumor vasculature assessed through dynamic contrast-enhanced magnetic resonance imaging.
    Zhang L; Zhao W; Liang C; Yi X; Pei Y; Lin Y; He J; Li W
    Oncol Rep; 2016 Sep; 36(3):1339-44. PubMed ID: 27431919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel synthetic small molecule YF-452 inhibits tumor growth through antiangiogenesis by suppressing VEGF receptor 2 signaling.
    Liu Y; He Y; Yang F; Cong X; Wang J; Peng S; Gao D; Wang W; Lan L; Ying X; Liu M; Chen Y; Yi Z
    Sci China Life Sci; 2017 Feb; 60(2):202-214. PubMed ID: 28194552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiangiogenic and Antitumor Activities of Aflibercept, a Soluble VEGF Receptor-1 and -2, in a Mouse Model of Hepatocellular Carcinoma.
    Torimura T; Iwamoto H; Nakamura T; Abe M; Ikezono Y; Wada F; Sakaue T; Masuda H; Hashimoto O; Koga H; Ueno T; Yano H
    Neoplasia; 2016 Jul; 18(7):413-24. PubMed ID: 27435924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A fusion protein with the receptor-binding domain of vascular endothelial growth factor-A (VEGF-A) is an antagonist of angiogenesis in cancer treatment: Simultaneous blocking of VEGF receptor-1 and 2.
    Tseng FJ; Chen YC; Lin YL; Tsai NM; Lee RP; Chung YS; Chen CH; Liu YK; Huang YS; Hwang CH; Lai YK; Liao KW
    Cancer Biol Ther; 2010 Nov; 10(9):865-73. PubMed ID: 20818186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases.
    Lee L; Sharma S; Morgan B; Allegrini P; Schnell C; Brueggen J; Cozens R; Horsfield M; Guenther C; Steward WP; Drevs J; Lebwohl D; Wood J; McSheehy PM
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):761-71. PubMed ID: 16172907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
    Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
    Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ferulic Acid Exerts Anti-Angiogenic and Anti-Tumor Activity by Targeting Fibroblast Growth Factor Receptor 1-Mediated Angiogenesis.
    Yang GW; Jiang JS; Lu WQ
    Int J Mol Sci; 2015 Oct; 16(10):24011-31. PubMed ID: 26473837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiangiogenic activity of berberine is mediated through the downregulation of hypoxia-inducible factor-1, VEGF, and proinflammatory mediators.
    Hamsa TP; Kuttan G
    Drug Chem Toxicol; 2012 Jan; 35(1):57-70. PubMed ID: 22145808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diosmetin inhibits tumor development and block tumor angiogenesis in skin cancer.
    Choi J; Lee DH; Park SY; Seol JW
    Biomed Pharmacother; 2019 Sep; 117():109091. PubMed ID: 31228803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinically relevant concentrations of lidocaine inhibit tumor angiogenesis through suppressing VEGF/VEGFR2 signaling.
    Gao J; Hu H; Wang X
    Cancer Chemother Pharmacol; 2019 Jun; 83(6):1007-1015. PubMed ID: 30887179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical evaluation of tumor microvascular response to a novel antiangiogenic/antitumor agent RO0281501 by dynamic contrast-enhanced MRI at 1.5 T.
    Muruganandham M; Lupu M; Dyke JP; Matei C; Linn M; Packman K; Kolinsky K; Higgins B; Koutcher JA
    Mol Cancer Ther; 2006 Aug; 5(8):1950-7. PubMed ID: 16928815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.